Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-403.03%
↓ 144% below average
Average (39q)
-165.35%
Historical baseline
Range
High:110.15%
Low:-4500.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -403.03% |
| Q2 2025 | 110.15% |
| Q1 2025 | -92.59% |
| Q4 2024 | 32.50% |
| Q3 2024 | 9.09% |
| Q2 2024 | -10.00% |
| Q1 2024 | 9.09% |
| Q4 2023 | 8.33% |
| Q3 2023 | -20.00% |
| Q2 2023 | -4.49% |
| Q1 2023 | 36.20% |
| Q4 2022 | -36.36% |
| Q3 2022 | -14.58% |
| Q2 2022 | 12.73% |
| Q1 2022 | 47.62% |
| Q4 2021 | -10.53% |
| Q3 2021 | 5.00% |
| Q2 2021 | -11.11% |
| Q1 2021 | 0.00% |
| Q4 2020 | 25.00% |
| Q3 2020 | -20.00% |
| Q2 2020 | 0.00% |
| Q1 2020 | 44.44% |
| Q4 2019 | 75.17% |
| Q3 2019 | -253.66% |
| Q2 2019 | 2.38% |
| Q1 2019 | -27.27% |
| Q4 2018 | 25.00% |
| Q3 2018 | -4500.00% |
| Q2 2018 | 103.13% |
| Q1 2018 | 50.77% |
| Q4 2017 | -209.52% |
| Q3 2017 | 36.36% |
| Q2 2017 | 2.94% |
| Q1 2017 | 91.56% |
| Q4 2016 | -989.19% |
| Q3 2016 | 85.02% |
| Q2 2016 | -696.77% |
| Q1 2016 | -210.00% |
| Q4 2015 | 82.46% |